PDF Solutions, a semiconductor data solutions provider, will announce its third quarter fiscal 2026 financial results on November 5, 2026, after market close. CEO John Kibarian and CFO Adnan Raza will host a live teleconference to discuss the results, offering investors and analysts a chance to engage directly. This update is important as it reflects the company’s ongoing performance in the semiconductor industry, which is critical for investors tracking tech sector developments. The call will be webcast and available for replay on the company’s website.
PDF Solutions' upcoming Q3 fiscal 2026 results provide context for readers tracking tech sector performance. As of October 20, 2026, 81 of 150 priced Technology-sector US stocks on Pluang rose while 67 fell. Notable movers include TWLO at USD 242.00 with a -11.49% change and 100% buy order activity, OKTA at USD 185.00 with a -11.28% change and 100% sell order activity, and AXTI at USD 56.96 with a +10.67% change and 58% buy order activity; typical hold times range from 17 to 56 days.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
